Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

First International Summit on Interventional Pharmacoeconomics

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Apr

Today In Oncology

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Related Videos

Garth Strohbehn, MD, MPhil, on Applied Clinical Pharmacology in a Crisis: Interventional Pharmacoeconomics and COVID-19

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Clifford A. Hudis, MD: Are Cancer Drug Prices in the U.S. the Problem or the Symptom?

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

David T. Rubin, MD, on Biosimilars for Inflammatory Bowel Disease

Is Standard of Care Optimal for the Individual Patient?

LuPSMA-617 and Pembrolizumab in mCRPC

ASH-ISTH Create Guidelines for Pediatric VTE Prophylaxis

Asbestos-Free Talc Not Associated With Increased Risk for Respiratory Cancers

New Molecular-Based Model for Classification and Risk in Chronic Myelomonocytic Leukemia